The EU's health regulator is expected to decide in the first half of 2026 on the expanded use of Arexvy, GSK said, adding that it was working on making similar applications to U.S. and Japanese ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns, Merck announced.Merck said it plans to make ...

GSK seeks EU approval for RSV vaccine for younger adults EU decision on expanded use expected by first half of 2026 June 13 (Reuters) - GSK (GSK.L), opens new tab has applied to the European ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from respiratory ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

Prediabetes interventions at forefront of treatment: What to know Moderna’s RSV shot was the first non-COVID-19 mRNA vaccine to be approved in the United States.